Coronavirus disease-2019 and heart: assessment of troponin and cardiovascular comorbidities as prognostic markers in patients hospitalized with coronavirus disease-2019 in a tertiary center in Brazil

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPINESI, Henrique Trombini
dc.contributor.authorGIUGNI, Fernando Rabioglio
dc.contributor.authorMATUCK, Bruna Romanelli Scarpa
dc.contributor.authorPITTA, Fabio Grusnpun
dc.contributor.authorGARZILLO, Cibele Larrosa
dc.contributor.authorLIMA, Eduardo Gomes
dc.contributor.authorKALIL FILHO, Roberto
dc.contributor.authorSERRANO JUNIOR, Carlos Vicente
dc.contributor.groupauthorHCFMUSP COVID 19 Study Grp
dc.date.accessioned2023-10-30T14:25:28Z
dc.date.available2023-10-30T14:25:28Z
dc.date.issued2023
dc.description.abstractOBJECTIVE: Our study aimed to evaluate the correlation of cardiac troponin T levels with comorbidities and in-hospital outcomes in patients with coronavirus disease-2019 in Brazil.METHODS: Data from a cohort of 3,596 patients who were admitted with suspected coronavirus disease-2019 in a Brazilian tertiary center, between March and August 2020, were reviewed. A total of 2,441 (68%) patients had cardiac troponin T determined in the first 72 h of admission and were stratified into two groups: elevated cardiac troponin T (cardiac troponin T >0.014 ng/mL) and normal cardiac troponin T. Associations between troponin, comorbidities, biomarkers, and outcomes were assessed. Regression models were built to assess the association of several variables with in-hospital mortality.RESULTS: A total of 2,441 patients were embraced, of which 924 (38%) had normal cardiac troponin T and 1,517 (62%) had elevated cardiac troponin T. Patients with elevated cardiac troponin T were older and had more comorbidities, such as cardiovascular disease, hypertension, diabetes, arrhythmia, renal dysfunction, liver disease, stroke, cancer, and dementia. Patients with abnormal cardiac troponin T also had more altered laboratory parameters on admission (i.e., leukocytes, C-reactive protein, D-dimer, and B-type natriuretic peptide), as well as more need for intensive care unit, vasoactive drugs, mechanical ventilation, dialysis, and blood transfusion. All-cause mortality was markedly higher among patients with increased cardiac troponin T (42 vs. 16%, P<0.001). Multiple regression analysis demonstrated that in-hospital mortality was not independently associated with troponin elevation.CONCLUSION: This study showed that cardiac troponin T elevation at admission was common and associated with several comorbidities, biomarkers, and clinical outcomes in patients hospitalized with coronavirus disease-2019, but it was not an independent marker of in-hospital mortality.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationREVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.69, n.7, article ID e20230350, 8p, 2023
dc.identifier.doi10.1590/1806-9282.20230350
dc.identifier.eissn1806-9282
dc.identifier.issn0104-4230
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/56019
dc.language.isoeng
dc.publisherASSOC MEDICA BRASILEIRAeng
dc.relation.ispartofRevista da Associacao Medica Brasileira
dc.rightsopenAccesseng
dc.rights.holderCopyright ASSOC MEDICA BRASILEIRAeng
dc.subjectCOVID-19eng
dc.subjectTroponineng
dc.subjectCardiovascular diseaseeng
dc.subjectMyocardial ischemiaeng
dc.subject.othermyocardial injuryeng
dc.subject.wosMedicine, General & Internaleng
dc.titleCoronavirus disease-2019 and heart: assessment of troponin and cardiovascular comorbidities as prognostic markers in patients hospitalized with coronavirus disease-2019 in a tertiary center in Brazileng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcHENRIQUE TROMBINI PINESI
hcfmusp.contributor.author-fmusphcFERNANDO RABIOGLIO GIUGNI
hcfmusp.contributor.author-fmusphcBRUNA ROMANELLI SCARPA
hcfmusp.contributor.author-fmusphcFABIO GRUNSPUN PITTA
hcfmusp.contributor.author-fmusphcCIBELE LARROSA GARZILLO
hcfmusp.contributor.author-fmusphcEDUARDO GOMES LIMA
hcfmusp.contributor.author-fmusphcROBERTO KALIL FILHO
hcfmusp.contributor.author-fmusphcCARLOS VICENTE SERRANO JUNIOR
hcfmusp.description.articlenumbere20230350
hcfmusp.description.issue7
hcfmusp.description.volume69
hcfmusp.origemWOS
hcfmusp.origem.pubmed37466607
hcfmusp.origem.scieloSCIELO:S0104-42302023000700619
hcfmusp.origem.scopus2-s2.0-85165518952
hcfmusp.origem.wosWOS:001033719400022
hcfmusp.publisher.citySAO PAULOeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.reference[Anonymous], COR BRASeng
hcfmusp.relation.referenceBastos ML, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2516eng
hcfmusp.relation.referenceChangal K, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-021-02450-3eng
hcfmusp.relation.referenceCorman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045eng
hcfmusp.relation.referenceCunningham JW, 2021, CIRCULATION, V144, P177, DOI 10.1161/CIRCULATIONAHA.121.054969eng
hcfmusp.relation.referenceGuimaraes PO, 2021, IJC HEART VASC, V36, DOI 10.1016/j.ijcha.2021.100853eng
hcfmusp.relation.referenceGuo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017eng
hcfmusp.relation.referenceHan H, 2020, J MED VIROL, V92, P819, DOI 10.1002/jmv.25809eng
hcfmusp.relation.referenceHuang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-Xeng
hcfmusp.relation.referenceImazio M, 2020, HEART, V106, P1127, DOI 10.1136/heartjnl-2020-317186eng
hcfmusp.relation.referenceIorio A, 2022, AM J CARDIOL, V167, P125, DOI 10.1016/j.amjcard.2021.11.054eng
hcfmusp.relation.referenceLala A, 2020, J AM COLL CARDIOL, V76, P533, DOI [10.1016/j.jacc.2020.06.007, 10.1101/2020.04.20.20072702]eng
hcfmusp.relation.referenceMarcilio I, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2166eng
hcfmusp.relation.referenceMetkus TS, 2021, CIRCULATION, V143, P553, DOI 10.1161/CIRCULATIONAHA.120.050543eng
hcfmusp.relation.referenceNasir Kansestani Atefeh, 2021, J Tehran Heart Cent, V16, P1, DOI 10.18502/jthc.v16i1.6594eng
hcfmusp.relation.referenceOmland T, 2020, CIRCULATION, V142, P1878, DOI 10.1161/CIRCULATIONAHA.120.050089eng
hcfmusp.relation.referencePolcwiartek Christoffer, 2022, Am Heart J Plus, V14, P100131, DOI 10.1016/j.ahjo.2022.100131eng
hcfmusp.relation.referenceSandoval Y, 2020, J AM COLL CARDIOL, V76, P1244, DOI 10.1016/j.jacc.2020.06.068eng
hcfmusp.relation.referenceShi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950eng
hcfmusp.relation.referenceTorres-Torres J, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14020271eng
hcfmusp.relation.referencevon Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120eng
hcfmusp.relation.referenceZhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3eng
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublicationbd5b74ea-0f97-4a4f-8d10-c5038caf1eac
relation.isAuthorOfPublication6bc84a15-5eb1-45a7-938e-f982121c1db0
relation.isAuthorOfPublication429df4f2-8550-4660-a2c4-033e817d5be9
relation.isAuthorOfPublication35ce8a2e-9a92-4f00-b08b-432dcb07303e
relation.isAuthorOfPublicationfa91ff34-659d-496b-8026-4b56f389967e
relation.isAuthorOfPublicationa354095f-ee4d-48b4-8684-c6cdfa32b731
relation.isAuthorOfPublicationc934e4bf-7bb3-4e4d-aaac-07d8be41a3ac
relation.isAuthorOfPublication2c371782-3a13-4c0b-8caf-b4ad0359b67b
relation.isAuthorOfPublication.latestForDiscoverybd5b74ea-0f97-4a4f-8d10-c5038caf1eac
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
art_PINESI_Coronavirus_disease2019_and_heart_assessment_of_troponin_and_2023.PDF
Tamanho:
370.24 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)